Expert in Life Science clinical drug development. Manage large global teams to serve biotech and large pharma C-suite clients in portfolio/pipeline strategy, asset strategy, trial acceleration, M&A, due diligence, CRO contracting, and organizational design. Example engagements include:• Led global portfolio strategy at large pharmaco to inform $10B+ R&D budget and M&A strategy• Created rare disease pipeline strategy and BD strategy at large pharmaco• Conducted due diligence for a $300M+ royalty acquisition and $10B+ acquisition of a trial services provider• Accelerated oncology asset development across 6 active trials and developed indication expansion strategy• Facilitated reorganization of global development (9K+ employees) at large pharmaco to streamline operations

Conducted due diligence on early-stage life science ventures for $800m fund and led pipeline landscape assessments in the cardiovascular and neurodegenerative disease spaces to inform investment strategies

• Developed R&D strategies for Fortune 500 pharmaceutical firms• Led global teams to accelerate drug development pipelines by optimizing clinical trial design• Leveraged big-data analytics with real-world data sets to drive insights

• Designed and coordinated 6 industry-sponsored investigator initiated clinical trials• Led global teams on studies that refined therapies and optimized patient outcomes• Secured funding from industry sponsors and outlined multi-million-dollar budgets• Conducted 15+ independent studies, authored 26 peer-reviewed publications in top medical journals, and presented results to audiences of 50-600 at 3 international symposiaConsultant for Optos, plc (subsidiary of Nikon)• Lead investigator on patented technology that was incorporated into the entire product line.

• Investigated efficacy of therapies for PTSD, methamphetamine, cocaine, and nicotine addiction in 7 clinical trials• Authored 2 peer-reviewed publications